Rituximab treatment of severe pemphigus: Long-term results including immunologic follow-up

Journal of the American Academy of Dermatology

Volumn 67, Issue 4, 2012, Pages 623-629

  Reguiai, Ziad ^a   Tabary, Thierry ^a   Maizières, Michael ^a   Bernard, Philippe ^a  

^a SERVICE DE DERMATOLOGIE   (France)

Author keywords

anti desmoglein autoantibodies; enzyme linked immunosorbent assay; pemphigus foliaceus; pemphigus vulgaris; rituximab

Indexed keywords

AZATHIOPRINE; DAPSONE; DESMOGLEIN 3 ANTIBODY; DESMOGLEIN ANTIBODY; IMMUNOGLOBULIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB;

ABSENCE OF SIDE EFFECTS; ACNE; ADOLESCENT; ADULT; AGED; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; CHILD; CLINICAL ARTICLE; CORTICOSTEROID THERAPY; DEPRESSION; DIABETES MELLITUS; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HEMOLYTIC ANEMIA; HEPATITIS; HUMAN; HYPERTENSION; INSOMNIA; KAPOSI JULIUSBERG SYNDROME; KIDNEY FAILURE; LONG TERM CARE; MAINTENANCE THERAPY; MALE; MOOD CHANGE; MULTIPLE CYCLE TREATMENT; OBESITY; OSTEOPOROSIS; PEMPHIGUS FOLIACEUS; PEMPHIGUS VULGARIS; PRESCHOOL CHILD; PRIORITY JOURNAL; RELAPSE; REMISSION; RETROSPECTIVE STUDY; SEPTICEMIA; SIDE EFFECT; STAPHYLOCOCCUS INFECTION; STOMACH ULCER; TACHYCARDIA; TREATMENT DURATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; AUTOANTIBODIES; CHILD; CHILD, PRESCHOOL; DESMOGLEIN 3; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PEMPHIGUS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84866344623     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2011.12.019     Document Type: Article

References (28)

1. J.R. Stanley Pemphigus and pemphigoid as paradigms of organ-specific, autoantibody-mediated diseases J Clin Invest 83 1989 1443 1448
2. J.R. Stanley Cell adhesion molecules as targets of autoantibodies in pemphigus and pemphigoid, bullous diseases due to defective epidermal cell adhesion Adv Immunol 53 1993 291 325
3. M. Amagai Desmoglein as a target in autoimmunity and infection J Am Acad Dermatol 48 2003 244 252
4. L.K. Martin, V.P. Werth, E.V. Villanueva, and D.F. Murrell A systematic review of randomized controlled trials for pemphigus vulgaris and pemphigus foliaceus J Am Acad Dermatol 64 2011 903 908
5. L.C. Strowd, S.L. Taylor, J.L. Jorizzo, and M.R. Namazi Therapeutic ladder for pemphigus vulgaris: emphasis on achieving complete remission J Am Acad Dermatol 64 2011 490 494
6. J.C. Bystryn Adjuvant therapy of pemphigus Arch Dermatol 120 1984 941 951
7. P.J. Carson, A. Hameed, and A.R. Ahmed Influence of treatment on the clinical course of pemphigus vulgaris J Am Acad Dermatol 34 1996 645 652
8. J.C. Bystryn, and N.M. Steinman The adjuvant therapy of pemphigus: an update Arch Dermatol 132 1996 203 212
9. N. Sami, A. Qureshi, E. Ruocco, and A.R. Ahmed Corticosteroid-sparing effect of intravenous immunoglobulin therapy in patients with pemphigus vulgaris Arch Dermatol 138 2002 1158 1162
10. M. Amagai, S. Ikeda, H. Shimizu, H. Iizuka, K. Hanada, and S. Aiba A randomized double-blind trial of intravenous immunoglobulin for pemphigus J Am Acad Dermatol 60 2009 595 603
11. A.R. Ahmed, Z. Spigelman, L.A. Caracini, and M.R. Posner Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin N Engl J Med 355 2006 1772 1779
12. P. Joly, H. Mouquet, J.C. Roujeau, M. D'Incan, D. Gilbert, and S. Jacquot A single cycle of rituximab for the treatment of pemphigus N Engl J Med 357 2007 545 552
13. W.F. Lever Pemphigus and pemphigoid J Am Acad Dermatol 1 1979 2 31
14. M. Amagai, A. Komai, T. Hashimoto, Y. Shirakata, K. Hashimoto, and T. Yamada Usefulness of enzyme linked immunosorbent assay using recombinant desmogleins 1 and 3 for the diagnosis of pemphigus Br J Dermatol 140 1999 351 357
15. S.W. Cheng, M. Kobayashi, K. Kinoshita-Kuroda, K. Tanikawa, M. Amagai, and T. Nishikawa Monitoring disease activity in pemphigus with enzyme-linked immunosorbent assay using recombinant desmogleins 1 and 3 Br J Dermatol 147 2002 261 265
16. D.F. Murrell, S. Dick, A.R. Ahmed, M.A. Barnadas, L. Borradori, and J.C. Bystryn Consensus statement on definitions of disease, endpoints and therapeutic response for pemphigus J Am Acad Dermatol 58 2008 1043 1046
17. E. Schmidt, E.B. Broker, and E. Goebeler Rituximab in treatment-resistant autoimmune blistering skin disorders Clin Rev Allergy Immunol 34 2008 56 64
18. H.M. Gurcan, D.B. Keskin, J.N. Stern, N.A. Nitzberg, H. Shekhani, and A.R. Ahmed A review of the current use of rituximab in autoimmune diseases Int Immunopharmacol 9 2009 10 25
19. C. Stamm, and J. Thivolet Weaning of systemic steroid treatment in pemphigus: a twelve-year retrospective study on 270 French patients Eur J Dermatol 13 1995 664 670
20. D. Jiao, and J.C. Bystryn Sensitivity of indirect immunofluorescence, substrate specificity and immunoblotting in the diagnosis of pemphigus J Am Acad Dermatol 37 1997 211 216
21. M. Amagai, K. Tsunoda, D. Zillikens, T. Nagai, and T. Nishikawa The clinical phenotype of pemphigus is defined by the anti-desmoglein autoantibody profile J Am Acad Dermatol 40 1999 167 170
22. K.E. Harman, P.T. Seed, M.J. Gratian, B.S. Bhogal, S.J. Challacombe, and M.M. Black The severity of cutaneous and oral pemphigus is related to desmoglein 1 and 3 antibody levels Br J Dermatol 144 2001 775 780
23. G. Cianchini, R. Corona, A. Frezzolini, M. Ruffeli, B. Didona, and P. Puddu Treatment of severe pemphigus with rituximab Arch Dermatol 143 2007 1033 1038
24. E.J. Kwon, J. Yamagami, T. Nishikawa, and M. Amagai Anti-desmoglein IgG autoantibodies in patients with pemphigus in remission J Eur Acad Dermatol Venereol 22 2008 1070 1075
25. A. Nagel, E. Podstawa, M. Eickmann, H.H. Müller, M. Hertl, and R. Eming Rituximab mediates a strong elevation of B-cell-activating factor associated with increased pathogen-specific IgG but not autoantibodies in pemphigus vulgaris J Invest Dermatol 129 2008 2202 2210
26. M. Amagai, A.R. Ahmed, Y. Kitajima, J.C. Bystyrn, Y. Milner, and R. Gniadecki Are desmoglein autoantibodies essential for the immunopathogenesis of pemphigus vulgaris or just 'witness of disease'? Exp Dermatol 15 2006 815 831
27. G. Zambruno, and L. Borradori Rituximab immunotherapy in pemphigus: therapeutic effects beyond B-cell depletion J Invest Dermatol 128 2008 2645 2647
28. H. Mouquet, P. Musette, M.L. Gougeon, S. Jacquot, B. Lemercier, and A. Lim B-cell depletion immunotherapy in pemphigus: effects on cellular and humoral immune responses J Invest Dermatol 128 2008 2859 2869